Shattuck Labs, Inc.
For the period ended Jun 30, 2026. Filed Aug 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 11, 2026
What changed in Risk Factors?
Read the current filingPrevious report: 10-Q
Period ended 2026-03-31; filed 2026-05-07.
0001628280-26-031661
Item 1A. Risk FactorsItem Unregistered Sales of Equity Securities and Use of ProceedsDefaults Upon Senior SecuritiesMine Safety DisclosuresOther InformationCurrent report: 10-Q
Period ended 2026-06-30; filed 2026-08-11.
0001628280-26-055483
Item 1A. Risk FactorsItem Unregistered Sales of Equity Securities and Use of ProceedsDefaults Upon Senior SecuritiesMine Safety DisclosuresOther InformationThe baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.
Compared 8 previous paragraphs and 9 current paragraphs.
4 unchanged; 2 reworded; 3 added; 1 removed; 1 previous and 0 current paragraphs rearranged.
Tables are not compared: 0 previous and 0 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.
A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.
Added paragraphs (3)
Current report
Recent Sales of Unregistered Securities
Current report
Issuer Purchases of Equity Securities
Removed paragraphs (1)
Previous report
The adoption of Dr. Pandite and Dr. Shukla's 10b5-1 plans were in accordance with both the Company's insider trading policy and SEC rules and regulations, on the date of adoption.
Reworded paragraphs (2)
Previous wording
Our business is subject to various risks, including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025. There have been no material changes from the risk factors disclosed in Item 1A of our Annual Report on Form 10-K.
Current wording
Our business is subject to various risks, uncertainties and other factors, including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025. There have been no material changes from the risk factors disclosed in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025.
Previous wording
On February 2, 2026, Arunthathy Nirmalini (Lini) Pandite, M.B.Ch.B., the Company's Chief Medical Officer, adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act (a “10b5-1 Plan”). Dr. Pandite’s 10b5-1 Plan provides for the potential sale of up to 83,514 shares of the Company’s common stock and will expire on the earlier of June 30, 2027 or the date when all shares under Dr. Pandite’s 10b5-1 Plan are sold.
Current wording
On June 12, 2026, Dr. Neil Gibson, amember of the Company's board of directors, adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act (a “10b5-1 Plan”). Dr. Gibson’s 10b5-1 Plan provides for the potential sale of up to 71,083 shares of the Company’s common stock and will expire on the earlier of February 26, 2027 or the date when all shares under Dr. Gibson’s 10b5-1 Plan are sold, subject to certain conditions.
Rearranged previous paragraphs (1)
Previous report — wording carried elsewhere
On February 2, 2026, Abhinav Shukla, PhD., the Company's Chief Technical Officer, adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. Dr. Shukla’s 10b5-1 Plan provides for the potential exercise of stock options to purchase up to 168,659 shares of the Company's common stock and subsequent sale of a portion of the exercised options to cover the exercise price and estimated income taxes associated with the exercise. The 10b5-1 Plan will expire on the earlier of January 29, 2027 or the date when all shares under Dr. Shuckla’s 10b5-1 Plan are exercised.